Company intelligence / Profile preview

VALANX Biotech

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

VALANX Biotech’s lead candidate, VLX101, a novel Interleukin‑2 conjugate developed with their proprietary site-specific protein conjugation platform, demonstrated promising preclinical efficacy in autoimmune disease models. The company’s approach enables precise half-life extension without the drawbacks of PEGylation. No clinical data yet; first-in-human studies are planned.

Therapeutic areas: Immunology
Modalities: ProteinProtein-drug conjugateRecombinant proteinSynthetic amino acid-based conjugates (platform)
Industry: Biotech

Drug pipeline

3 assets

VLX-ADC1

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Fina Biosolutions/FinaBio – partnership to develop ClickCRM for rapid vaccine development using VALANX's platform technology

Beyond the preview

Go deeper on VALANX Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VALANX Biotech.

Explore the full profile